Larimar Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Research and development | $154.2M | $73.3M | $27.7M | $24.2M | $38.4M |
| Operating expenses | $172.5M | $90.9M | $41.8M | $36.5M | $50.5M |
| Operating income | -$172.5M | -$90.9M | -$41.8M | -$36.5M | -$50.5M |
| Pretax income | -$165.7M | -$80.6M | -$36.9M | -$35.4M | -$50.6M |
| Income tax expense | $0 | $0 | $0 | $0 | $0 |
| Net income | -$165.7M | -$80.6M | -$36.9M | -$35.4M | -$50.6M |
| Balance Sheet | |||||
| Cash and equivalents | $85.4M | $33.2M | $26.7M | $26.8M | $70.1M |
| Current assets | $142.0M | $195.3M | $90.2M | $120.7M | $72.2M |
| Total assets | $145.8M | $200.2M | $95.9M | $126.4M | $78.7M |
| Current liabilities | $64.8M | $24.4M | $9.5M | $10.7M | $8.8M |
| Total liabilities | $67.8M | $28.4M | $14.2M | $15.5M | $14.3M |
| Stockholders' equity | $78.1M | $171.8M | $81.7M | $110.9M | $64.4M |
| Cash Flow Statement | |||||
| Cash from operations | -$113.2M | -$70.8M | -$33.5M | -$27.6M | -$42.1M |
| Depreciation and amortization | $350,000 | $318,000 | $311,000 | $318,000 | $326,000 |
| Stock-based compensation | $7.0M | $8.8M | $7.6M | $6.6M | $5.5M |
| Capital expenditure | $91,000 | $515,000 | $164,000 | $100,000 | $333,000 |
| Free cash flow | -$113.3M | -$71.3M | -$33.6M | -$27.7M | -$42.4M |
| Impairments | $0 | $0 | $0 | $0 | $0 |
Shares outstanding 103.9M · Free float 84.7%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.